| Autor: |
Lam, Audrey C., Li, Karen, Zhang, Xiao B., Li, Chi K., Fok, Tai F., Chang, Allan M.Z., James, Anthony E., Tsang, Kam S., Yuen, Patrick M.P., Lam, A C, Li, K, Zhang, X B, Li, C K, Fok, T F, Chang, A M, James, A E, Tsang, K S, Yuen, P M |
| Předmět: |
|
| Zdroj: |
Transfusion; Dec2001, Vol. 41 Issue 12, p1567-1576, 10p, 1 Chart, 15 Graphs |
| Abstrakt: |
Background: Ex vivo expansion of cord blood (CB) hematopoietic stem and progenitor cells increases cell dose and may reduce the severity and duration of neutropenia and thrombocytopenia after transplantation. This study's purpose was to establish a clinically applicable culture system by investigating the use of cytokines, serum-free media, and autologous plasma for the expansion of CB cells and the engraftment of expanded product in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice.Study Design and Methods: Enriched CB CD34+ cells were cultured in four media (Iscove's modified Dulbecco's medium with FCS, Gibco; X-Vivo-10, BioWhittaker; QBSF-60, Quality Biological; and StemSpan SFEM, Stem Cell Technologies) with four cytokine combinations (thrombopoietin [TPO], SCF, Flt-3 ligand [FL] with and without G-CSF, and/or IL-6). The effect of autologous CB plasma was also investigated. The read-out measures were evaluated on Days 8 and 12. After expansion at the optimized condition, cultured cells were transplanted into sublethally irradiated NOD/SCID mice. The engraftment of human CD45+ cells and subsets in the bone marrow, spleen, and peripheral blood was determined.Results: QBSF-60 or StemSpan SFEM supported high yields of early progenitors (CD34+ cells, Conclusion: The data supported the strategy of expansion. The optimized condition may be applicable to clinical expansion for the abrogation or reduction of posttransplant cytopenia. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text